Robert Hershberg
Vorstandsvorsitzender bei HILLEVAX, INC.
Vermögen: 10 Mio $ am 30.04.2024
Profil
Robert M.
Hershberg is the founder of VentiRx Pharmaceuticals, Inc. (founded in 2006) and HilleVax, Inc. (founded in 2020).
He held the title of President, Chief Executive Officer & Director at VentiRx Pharmaceuticals, Inc. from 2012 to 2017.
Currently, he is the Chairman, President & Chief Executive Officer at HilleVax, Inc. (founded in 2020).
In his current roles, Dr. Hershberg is an Independent Director at Recursion Pharmaceuticals, Inc. (since 2020), Fate Therapeutics, Inc. (since 2020), and Adaptive Biotechnologies Corp.
(since 2013).
He is also a Director at Cajal Neuroscience, Inc. and a Member at UW Medicine.
Previously, Dr. Hershberg served as an Independent Director at NanoString Technologies, Inc. from 2015 to 2022.
He was also an Independent Director at Silverback Therapeutics, Inc., a Director at Guide Therapeutics, Inc., and the Chief Scientific Officer & Executive VP at Celgene Corp.
from 2016 to 2019.
Additionally, he held the position of Vice President-Medical Genetics at Corixa Corp.
from 2001 to 2003 and Chief Medical Officer & Senior Vice President at Dendreon Corp.
from 2003 to 2006.
He was an Assistant Professor at Harvard Medical School.
Dr. Hershberg obtained his doctorate degree from The Salk Institute for Biological Studies in 1992.
He also holds undergraduate and doctorate degrees from the University of California, Los Angeles.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
HILLEVAX, INC
1,64% | 01.04.2024 | 812 856 ( 1,64% ) | 10 Mio $ | 30.04.2024 |
| 12.04.2024 | 38 619 ( 0,02% ) | 302 773 $ | 30.04.2024 | |
| 01.04.2024 | 75 968 ( 0,05% ) | 198 276 $ | 30.04.2024 | |
FATE THERAPEUTICS, INC.
0,01% | 31.03.2024 | 10 659 ( 0,01% ) | 41 250 $ | 30.04.2024 |
Aktive Positionen von Robert Hershberg
| Unternehmen | Position | Beginn |
|---|---|---|
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Direktor/Vorstandsmitglied | 01.02.2013 |
| RECURSION PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 20.03.2020 |
| FATE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.05.2020 |
| HILLEVAX, INC. | Vorstandsvorsitzender | 25.03.2020 |
| UW Medicine | Corporate Officer/Principal | - |
Cajal Neuroscience, Inc.
 Cajal Neuroscience, Inc. BiotechnologyHealth Technology Cajal Neuroscience is a biotechnology company that focuses on discovering new treatments for neurodegeneration. The company is based in Seattle, WA and was founded by Ian Peikon. The company uses advanced technologies such as integrative human genetics, multi-omics, functional genomics, and microscopy to accelerate their target and drug discovery. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Robert Hershberg
| Unternehmen | Position | Ende |
|---|---|---|
| NANOSTRING TECHNOLOGIES, INC. | Direktor/Vorstandsmitglied | 18.04.2022 |
| CELGENE | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
VentiRx Pharmaceuticals, Inc.
 VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Vorstandsvorsitzender | 01.03.2017 |
| ░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Robert Hershberg
| University of California, Los Angeles | Doctorate Degree |
| The Salk Institute for Biological Studies | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| NANOSTRING TECHNOLOGIES, INC. | Health Technology |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
| RECURSION PHARMACEUTICALS, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| HILLEVAX, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Health Technology |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson January 4, 2016 and is headquartered in Seattle, WA. | Health Technology |
Guide Therapeutics, Inc.
 Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | Health Technology |
Cajal Neuroscience, Inc.
Cajal Neuroscience, Inc. BiotechnologyHealth Technology Cajal Neuroscience is a biotechnology company that focuses on discovering new treatments for neurodegeneration. The company is based in Seattle, WA and was founded by Ian Peikon. The company uses advanced technologies such as integrative human genetics, multi-omics, functional genomics, and microscopy to accelerate their target and drug discovery. | Health Technology |
